We are an interdisciplinary research group. Our research efforts have been focusing on defining the efficacies of preventive and therapeutic approaches (drugs, exercise, and gene delivery) for mitochondrial dysfunction in multiple disease conditions.
To study the underlying mechanisms and potential treatment in the pathological developments (neurological dysfunction, cardiomyopathy, and muscle weakness) of Friedreich’s ataxia.
DOD/CDMRP (PI): 11/2023 – 11/2025
NIH/NINDS/R21 (Co-I): 4/2022 – 3/2025
UML Seed Grant (PI): 7/2023 – 6/2025
To study mitochondrial iron export therapy for doxorubicin-induced cardiotoxicity.
NIH/NHLBI/R01 (Co-I): 1/2023 – 12/2026
To study preventive strategy for mitochondrial copper cumulation in Wilson’s disease.
NIH/NICHD/R21 (Co-I): 9/2022 – 8/2024